PATIENT PRIVACY AND DATA CONFIDENTIALITY AND THE USE OF SECONDARY DATA

Author(s)

Bonnie B Dean, PhD, MPH, Principal Investigator1, Daniel Aguilar, MPH, Research Project Leader1, Joanna Whyte, MS, RD, MSPH, Senior Manager2, Robert Nordyke, PhD, MS, Director21Cerner LifeSciences, Beverly Hills, CA, USA; 2 Amgen, Inc., Thousand Oaks, CA, USA

OBJECTIVES: No well-defined standards, including provisions in HIPAA, currently provide clear guidance for merging, linking, and analyzing secondary health data that were originally collected for patient care, such as electronic medical record (EMR) data. A literature review explored factors that may affect potential risks of secondary data research from the perspective of patient privacy and data confidentiality. METHODS: The PubMed database and internet sites of CDC, DHHS, and patient advocacy groups were searched to identify publications from January 1, 1998 to March 7, 2008 involving patient privacy and secondary use of data. Search terms included (but were not limited to): confidentiality, privacy, consent, ethics, secondary data, secondary analysis, patient data, de-identified, and identifiable. RESULTS: A total of 33 documents were identified. Several discussion topics that address patient privacy within the context of secondary data research were identified in the literature. These issues were assessed and grouped into four domains: 1) concerns about inadequacy of patient consent [76% of articles] (eg, no patient consent is needed or that consent obtained for general research purposes may not be adequate for specific research hypotheses); 2) concerns about identifiability of the data and the degree to which the data can be de-identified [88%]; 3) concerns about data access, including monitoring, controlling, and regulation of data access [85%]; and (4) concerns about the investigators' objectives for analyzing and using the data [52%] (eg, epidemiology and surveillance studies caused less concern than did market research). CONCLUSIONS: We identified four recurrent themes in the evidence: they touched upon patient consent, identifiability of data, data access, and research objectives. Dialogue about these issues between investigators, research oversight administrators and patient advocates may help clarify standards to ensure that secondary data research is broadly acceptable from a patient privacy and data confidentiality perspective.

Conference/Value in Health Info

2009-05, ISPOR 2009, Orlando, FL, USA

Value in Health, Vol. 12, No. 3 (May 2009)

Code

PHP72

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Health Care Research

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×